SOLICITATION NOTICE
R -- PROCESSE ASSESSMENT OF ORANGE BOOK
- Notice Date
- 7/14/2008
- Notice Type
- Cancellation
- NAICS
- 541611
— Administrative Management and General Management Consulting Services
- Contracting Office
- Department of Health and Human Services, Food and Drug Administration, Office of Acquisitions and Grants Services, 5630 Fishers Lane, Room 2129, Rockville, Maryland, 20857-0001
- ZIP Code
- 20857-0001
- Solicitation Number
- FDA-SOL-08-00812
- Point of Contact
- ZetherineGore ,, Phone: (301) 827-5093
- E-Mail Address
-
zetherine.gore@fda.hhs.gov
- Small Business Set-Aside
- Total Small Business
- Description
- This is a combined synopsis/solicitation for commercial items prepared in accordance with the format in FAR 12.6, simplified acquisition procedures and the resultant purchase order will include all applicable provisions and clauses in effect through the Federal Acquisition Circular 05-24. This announcement constitutes the only solicitation and a written solicitation will not be issued. This synopsis, NAICS code, 541611 is to notify contractors that the government intends to issue a Purchase Order in accordance with FAR Part 13.106 for the following statement of work, under the simplified acquisition procedures. This is a total small business set-aside. Prospective offerors are responsible for downloading the solicitation and any amendments. It is the offeror's responsibility to monitor the FedBizOpps website for the release of any amendments to this solicitation. The Government reserves the right to award a contract without discussions if the Contracting Officer determines that the initial offer(s) is/are providing the Best Value and discussions are not necessary. This solicitation is issued as a Request for Proposal (RFP). The Food and Drug Administration (FDA) intends to award a purchase order for Business Process Assessment of Orange Book. The primary objectives of this project are to: The focus of this business process assessment is to document the current manual and automated processes to update the Orange Book and provide insight into potential areas of process improvement. The scope of the study includes an: (1) Examination of the Orange Book update processes performed by the Orange Book Team within DLPS: (a) Daily process for Drug Products and Patents (b) Monthly Drug Products, Patents and Exclusivity (c) Annual update of Drug Products, Patents and Exclusivity (2) Illustration of the high level flow of information and overall process to generate updates to the Orange Book (3) Comprehensive review and documentation of the work activities and information systems involved to update the online Orange Book (4) Identification of the roles of the Orange Book Team and other organizations, within OPS as well as in CDER, that are involved in either the update and/or verification of Orange Book information (5) Evaluation of automated processes and technologies used to update the Orange Book and/or validate Orange Book data in other CDER systems (6) Preparation of a report that describes our findings, analyses, and recommendations for improvement. 1. STATEMENT OF WORK Independently and not as an agent of the Government, the contractor shall furnish the necessary services and personnel, and otherwise do all things necessary for or incident to the performance of the work as described below. Description of Work/Deliverables Develop a process diagram of the Orange Book that will be discussed in a joint session with the Orange Book Team to validate the current process, activities, accountabilities, and handoffs. The joint session will also provide the forum to identify and/or resolve process issues and clarify information received during the interviews. Outstanding issues will be addressed and/or resolved with the Orange Book Team Leader and OGD management, as needed. Following the joint session, the Orange Book process diagram will be finalized and updates/clarifications to the roles documented for review by OGD and OPS management. Following the validation of the current process, the contractor will analyze the workflow, information systems, and technologies used to update the Orange Book. We will use various process improvement diagnostic techniques, as well as our understanding of information flow and data conversion requirements among various types of database technologies to diagnose redundant activities, both process and technology inefficiencies, and/or areas of unnecessary delay. The contractor will develop and present recommendations to potentially automate current labor intensive, manual processes used to update the Orange Book and evaluate the effectiveness of current technologies. The contractor will recommend manual and automated methods that may be applied to a future process to optimize the resources involved in updating the electronic Orange Book. The contractor prepare and present a briefing to OGD and OPS describing the validated current process to update the electronic Orange Book, as well as our findings and recommendations to improve the Orange Book process at a future date. 3. PERIOD OF PERFORMANCE One Year 4. PRICING The offeror’s fixed price should be provided for one year. 5. EVALUATION FACTORS FOR AWARD A. BEST VALUE CRITERIA - BASIS FOR AWARD The Offeror should demonstrate the statement of work is understood and offer a logical approach to its achievement. Award will be made to the offeror who is deemed most responsive, whose proposal conforms to all requirements, and is judged to represent the best value. To conduct a best value assessment, FDA will evaluate the offerors proposal submission based on Technical Elements, Price, and Past Performance as described below. Technical, Past Performance, and Price are of equal importance. As this is a best-value selection, the government may make tradeoffs in the factors below to arrive at a best value decision. The Government may award a task order on the basis of initial offers received, without discussions. Therefore, each initial offer should contain the Offeror's best terms from a cost and technical standpoint. B. EVALUATION CRITERIA The evaluation will be based on the completeness, thoroughness and demonstrated capabilities of the prospective Offeror in relation to the needs of the Statement of Work as set forth in the RFQ. Each proposal must document the feasibility of successful implementation of the requirements of the RFQ. Offerors must submit information sufficient to evaluate their proposals based on the detailed criteria listed below. Offerors should provide information on all of the following criteria. (1) Technical Solution The proposal must demonstrate a thorough understanding of the requirements of the Statement of Work and describe an approach which will demonstrate the achievement of timely and acceptable performance as describe in the Statement of Work and the Specifications therein. The proposal shall present a comprehensive statement of the problem, scope, and purpose of the project to demonstrate an understanding of the requirements from a management and technical standpoint. Detailed plan of work/program management, complete with quality control, including start-up service and follow-up service provisions and a detailed time line of commencement. (2) Qualifications and Availability of Personnel Offerors must demonstrate evidence of the qualifications, experience, and availability of professional and technical personnel comprising the necessary project staff. Personnel proposed to be assigned and available for work under the project shall be evaluated on their demonstrated, documented, and relevant expertise, education, availability, and experience. Supporting documentation about the experience, training, and education (e.g., resumes) of proposed personnel must be provided. (3) Past Performance Evaluation FDA will evaluate the offeror's past performance in the conduct of similar tasks and their relevance to this acquisition. (4) Price FDA will evaluate the offeror's submission/proposal on their ability to provide support at a reasonable and realistic price (to include any discounts offered). 7. PAYMENT SCHEDULE Payment will be made in equal monthly installments. 8. CCR Vendors must be registered in the Central Contractor Register (CCR) prior to the award of a contract. You may register by going to www.ccr.gov. You will need your Dun & Bradstreet number and banking information. 9. QUESTIONS DEADLINE: All questions are to be submitted via email to Zetherine.Gore@fda.hhs.gov no later than July 16, 2008 2:00pm EST. Answers to questions submitted will be provided by July 21st. 10. OFFERS DUE Two (2) copies of offeror’s proposal must be delivered no later than 2:00 p.m. local time on July 28, 2008. Proposal submissions are restricted to a limit of twenty-five (25) pages. Food and Drug Administration Attn: Zetherine Gore Food and Drug Administration 5630 Fishers Lane, Room 2075, HFA-500 Rockville, MD 20857 11. PROVISIONS AND CLAUSES: The provision at FAR 52.212-1, Instructions to Offerors Commercial Items applies to this solicitation. The following agenda has been attached to this provision: None. Offerors shall include a completed copy of the provision at FAR 52.212-3, Offeror Representations and Certifications Commercial Items. The clause at FAR 52.212-4, Contract Terms and Conditions, Commercial Items applies to this acquisition. The following agenda has been attached to the clause: None. The clause at FAR 52.212-5 Contract Terms and Conditions Required to Implement Statues or Executive Orders, Commercial Items applies to this acquisition. The following FAR clauses cited are applicable: FAR 52.217-8, FAR 52.222-26, FAR 52.222-35, FAR 52.222-36, and FAR 52.232-33. Clauses and provisions are incorporated by reference and apply to this acquisition. No telephone calls will be accepted.
- Web Link
-
FedBizOpps Complete View
(https://www.fbo.gov/?s=opportunity&mode=form&id=f718720b8f9d939a5e776a597ec54df0&tab=core&_cview=1)
- Record
- SN01613501-W 20080716/080714222804-0a48a1bc4c0a0543579bccead06b69cd (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |